• EN
  • SV
IDL Diagnostics
  • About
    • About IDL Diagnostics
    • Partners
    • Policy
    • Career
  • Products
    • Oncology
    • Bacteriology
    • Quality Assurance
    • Patents and Trademarks
  • News & Media
    • News
    • Press Releases
    • Events
    • Media
  • Investors
    • Financial calendar
    • Financial reports
      • Financial presentations
    • Share issues and Corporate transactions
      • Share issues
      • Corporate transactions
    • Share
      • The Share
      • Ownership structure
      • Insider trading
      • Analyst coverage
    • Certified Adviser
    • Corporate Governance
      • Management
      • Board of directors
      • Articles of association
      • Nomination Committee
      • General meeting
      • Annual General Meeting
    • IR contact
  • Contact
Select Page
IDL Biotech licensierar sin produktlinje för tumörmarkörer på den manuella plattformen radioimmunoassay till Beckman Coulter Diagnostics

IDL Biotech licensierar sin produktlinje för tumörmarkörer på den manuella plattformen radioimmunoassay till Beckman Coulter Diagnostics

Oct 2, 2019 | News

IDL Biotech meddelar att de har tecknat ett avtal med Beckman Coulter om licensiering av IDL Biotechs samtliga tumörmarkörer på den manuella plattformen radioimmunoassay (IRMA). Licensavtalet ger Beckman Coulter globala försäljningsrättigheter och möjliggör för IDL...
IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US.

IDL Biotech AB continues preparations to introduce its rapid test for bladder cancer, UBC Rapid, in the US.

Sep 17, 2019 | Financial News, Health & Information

IDL Biotech has started the work on mapping the US market. Read more here 
IDL Biotech launches TUBEX TF in Kenya

IDL Biotech launches TUBEX TF in Kenya

Sep 9, 2019 | Financial News, News, Typhiod fever

On September 17, 2019, IDL Biotech will launch the company’s rapid test for typhoid fever, TUBEX TF, in Kenya. Read more here
IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA

IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA

Jul 10, 2019 | Bladder cancer

IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company’s rapid test for bladder cancer. Read the press release here (in swedish)
Abstract shows the value of UBC Rapid

Abstract shows the value of UBC Rapid

Jul 4, 2019 | Bladder cancer

An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer. Read the press release here (in swedish)
« Older Entries
Next Entries »

Categories

  • Bladder cancer (12)
  • Breast Cancer (2)
  • Events (9)
  • Financial News (13)
  • Health & Information (3)
  • Lung cancer (3)
  • News (35)
  • Okategoriserade (3)
  • Typhiod fever (9)
Contact us

Email: info@idldiagnostics.com
Phone: +46 (0)8 799 67 50

More contact info
Address

Karlsbodavägen 39
168 67 Bromma
Stockholm
Sweden

Follow us
  • Follow
  • Follow

Recent Posts

  • Partnership Meetings and CLIA Focus in China
  • IDL Diagnostics att EAU26
  • Presentation of IDL Diagnostics Interim Report Q4 2025
  • IDL Diagnostics and concile at WHX Labs Dubai

About

  • About IDL Diagnostics
  • Partners
  • Policy
  • Career

Products

  • Oncology
  • Bacteriology
  • Quality Assurance
  • Patents and Trademarks

Investors

  • Financial calendar
  • Financial reports
  • Share issues and Corporate transactions
  • The Share
  • Certified Adviser
  • Corporate Governance
  • IR contact
© 21 March 2026 - All rights reserved IDL Diagnostics AB | Web design by Insign Webbyrå AB
IDL Diagnostics
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Alternativ
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Den tekniska lagringen eller åtkomst som används uteslutande för anonyma statistiska ändamål. Utan en stämningsansökan, frivillig efterlevnad från din Internetleverantör, eller ytterligare register från en tredje part, kan information som lagras eller hämtas endast för detta ändamål vanligtvis inte användas för att identifiera dig.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}